Imagine the control room of a nuclear plant built decades ago. The dials are analog and the spare parts are getting harder to find. This is the reality for much of the global nuclear fleet, and Mirion Technologies, Inc. NYSE:MIR is the company helping operators drag these facilities into the modern era. By providing essential radiation detection and medical safety tools, Mirion sits at the crossroads of a global energy transition and a high tech medical revolution. With a massive $1.1 billion backlog, the business is no longer just waiting for a nuclear renaissance; it's currently building the infrastructure to support it.
Potential Bull Cases
1. A Generational Nuclear Super Trend Is Transforming Long-Term Demand
Nuclear power is no longer a fringe energy source; it's becoming the backbone of the global transition to carbon-free power. The world currently operates about 400 gigawatts of nuclear capacity, but projections from the World Nuclear Association suggest a tripling to nearly 1.5 terawatts by 2050. For Mirion, this represents a massive, multiyear build out. In the second quarter of 2026, the company reported a total backlog of more than $1.1 billion, which is 40% higher than the same period last year. Management is seeing the first wave of this demand in catch-up capital spending as operators finally replace aging instrumentation that has been ignored for years. This cycle provides a predictable growth engine for the next decade.
2. High Switching Costs Create a Durable Moat Within the Global Installed Base
Mirion doesn't just sell gadgets; it provides the nervous system for nuclear safety. Approximately 80% of its nuclear power revenue comes from the existing installed base. Once a facility integrates Mirion's instrumentation and control systems, the costs and risks of switching to a rival are prohibitively high. This creates a source of recurring and repeat revenue that remains steady even when new plant construction slows. In the second quarter of 2026, orders from the operating fleet grew nearly 40% year over year excluding recent acquisitions. As plants move toward life extensions and power upgrades to run for another 20 years, they become even more dependent on Mirion's specialized hardware and digital platforms.
3. Small Modular Reactors Provide a High-Growth Option for the Future
While massive traditional reactors provide the base, small modular reactors (SMRs) represent the growth alpha. These smaller, flexible designs are moving from the drawing board to reality faster than many expected. Mirion is positioning itself as a primary supplier for this new generation of nuclear technology. In the second quarter of 2026, the company booked $49 million in SMR orders, an increase of $42 million compared to the previous year. Management noted that it has a right to win in this category because its technology is already baked into several advanced reactor designs. As SMRs move toward commercial deployment, Mirion is set to capture a larger slice of a much more agile market.
4. High-Margin Software Is Quietly Improving the Medical Segment Mix
Beyond the reactor floor, Mirion is a major player in cancer treatment and medical safety. While medical hardware sales can be lumpy, the company is aggressively pivoting toward software solutions like SunCHECK and PlanAI. In the first half of 2026, the nuclear medicine software business generated strong double-digit order growth. This shift is critical because software carries higher margins and stickier customer relationships than one-off equipment sales. Even as some hardware orders saw delays recently, medical segment adjusted EBITDA margins expanded in the second quarter of 2026. This reflects a better product mix and the growing influence of recurring software fees that help insulate the business from hospital capital spending cycles.
5. Strong Operating Leverage Paves a Clear Path to 30% Margins
The business model is reaching an inflection point where revenue growth translates into even faster profit growth. Management has set an audacious target of a 30% adjusted EBITDA margin by 2028, and the building blocks are falling into place. In the second quarter of 2026, adjusted EBITDA rose more than 27% to $65.3 million. Margins expanded to 24.5% as the company benefited from favorable pricing and the integration of high-performing acquisitions like Paragon. Because Mirion has a high degree of fixed-cost coverage in its factories, every incremental dollar of revenue carries a high contribution margin. As the company optimizes its supply chain and applies artificial intelligence to internal workflows, the bottom line should grow significantly faster than the top line.
Potential Bear Cases
1. Geopolitical Tensions and Trade Barriers Can Evaporate Backlog Overnight
The global nature of the nuclear industry is a double-edged sword. While Mirion has a presence in 12 countries, it is highly susceptible to shifts in international relations. This risk became concrete in July 2026 when the company experienced a $18 million cancellation for a Chinese new-build order that had been on the books since 2019. Stalled progress at the site and ongoing geopolitical friction between the U.S. and China effectively killed the project. While the financial impact of this specific event was immaterial to the full-year guide, it highlights a broader threat. If trade restrictions or sanctions tighten, Mirion could lose access to significant portions of the international market where it currently holds a dominant position.
2. Persistent Medical Hardware Delays Suggest a Fickle Customer Base
The medical segment has recently struggled with delayed customer demand that threatens to dampen growth. In the second quarter of 2026, organic revenue in the medical segment declined by 1% as hospitals paused hardware orders in nuclear medicine and dosimetry. While management characterizes this as a delay rather than a permanent loss of business, it points to a vulnerability. Hospitals are facing budget constraints and are waiting for more clarity in the drug pipeline before committing to expensive equipment upgrades. If these hardware delays persist or turn into outright cancellations, it will put more pressure on the software side of the business to carry the entire segment's growth targets.
3. A Heavy Debt Load Leaves Little Room for Future Execution Errors
Mirion's aggressive growth strategy has come at the cost of a significant debt load. The company ended the second quarter of 2026 with approximately $1.2 billion in total debt. While the business generates healthy adjusted free cash flow, which reached $49 million in the recent quarter, a large portion of that cash is earmarked for debt service and interest payments. This financial leverage creates a narrow path for management. To meet its full-year guidance, the company requires a massive step-up in organic growth during the second half of 2026. Any slip in execution, a downturn in nuclear demand, or a spike in interest rates could make this debt burden much more difficult to manage and limit the capital available for further acquisitions.
The Moneyball Verdict: 75 out of 100
Our proprietary Moneyball scoring system assigns Mirion Technologies an overall Superscore of 75 out of 100, placing it in the Strong category. The Superscore is an AI-powered score that evaluates a company's overall strength by combining financial performance, product market position, technological capabilities, leadership quality, and relative valuation. It represents the unification of all our scores into a single score for public companies, with five rating bands: Exceptional (90-100), Strong (75-89), Above Average (60-74), Average (40-59), and Cautious (0-39). This score places the company in the Top ~21% of all companies we score, or ahead of roughly 79 out of every 100 companies in our database.
Mirion operates as the nervous system for nuclear safety. This position makes high switching costs far more significant than short-term hardware delays. The Strong score corroborates the bull thesis that a $1.1 billion backlog and a global nuclear expansion provide a massive margin of safety. While debt and geopolitics create friction, the company remains the go-to partner as the world upgrades its reactor infrastructure.